Abstract:Although various approaches exist for treating cancer, chemotherapy continues to hold a prominent role in the management of this disease. Besides, microtubules serve as a vital component of the cellular skeleton, playing a pivotal role in the process of cell division making it an attractive target for cancer treatment. Hence, the scope of this work was adapted to design and synthesize new anti‐tubulin tetrabromophthalimide hybrids (3‐17) with colchicine binding site (CBS) inhibitory potential. The conducted in vitro studies showed that compound 16 displayed the lowest IC50 values (11.46 μM) at the FaDu cancer cell lines, whereas compound 17 exhibited the lowest IC50 value (13.62 μM) at the PC3 cancer cell line. However, compound 7b exhibited the lowest IC50 value (11.45 μM) at the MDA‐MB‐468 cancer cell line. Moreover, compound 17 was observed to be the superior antitumor candidate against all three tested cancer cell lines (MDA‐MB‐468, PC3, and FaDu) with IC50 values of 17.22, 13.15, and 13.62 μM, respectively. In addition, compound 17 showed a well‐established upregulation of apoptotic markers (Caspases 3, 7, 8, and 9, Bax, and P53). Moreover, compound 17 induced downregulation of the antiapoptotic markers (MMP2, MMP9, and BCL‐2). Furthermore, the colchicine binding site inhibition assay showed that compounds 15a and 17 exhibited particularly significant inhibitory potentials, with IC50 values of 23.07 and 4.25 μM, respectively, compared to colchicine, which had an IC50 value of 3.89 μM. Additionally, cell cycle analysis was conducted, showing that compound 17 could prompt cell cycle arrest at both the G0‐G1 and G2‐M phases. On the other hand, a molecular docking approach was applied to investigate the binding interactions of the examined candidates compared to colchicine towards CBS of the β‐tubulin subunit. Thus, the synthesized tetrabromophthalimide hybrids can be regarded as outstanding anticancer candidates with significant apoptotic activity.

Synthesis and characterization of bis-amide SSE1917 as a microtubule-stabilizing anticancer agent

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

The microtubule cytoskeleton: A validated target for the development of 2-Aryl-1 H -benzo[ d ]imidazole derivatives as potential anticancer agents

Synthesis and biological evaluation of 2-aryl-benzimidazole derivatives of dehydroabietic acid as novel tubulin polymerization inhibitors

Design and synthesis of novel tetrabromophthalimide derivatives as potential tubulin inhibitors endowed with apoptotic induction for cancer treatment

Design, synthesis, and bioevaluation of diarylpyrimidine derivatives as novel microtubule destabilizers

Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site

Synthesis, Biological Evaluation, and Molecular Docking Studies of 2,6-Dinitro-4-(trifluoromethyl)phenoxysalicylaldoxime Derivatives As Novel Antitubulin Agents.

Concise Synthesis and Biological Evaluation of 2-Aroyl-5-amino Benzo[b]thiophene Derivatives As a Novel Class of Potent Antimitotic Agents

Synthesis and Antiproliferative Evaluation of 3-Chloroazetidin-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4

Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities.

Discovery of N-benzylarylamide derivatives as novel tubulin polymerization inhibitors capable of activating the Hippo pathway

Design, Synthesis and Characterization of Potent Microtubule Inhibitors with Dual Anti-Proliferative and Anti-Angiogenic Activities

Synthesis, Anti-Cancer Evaluation of Benzenesulfonamide Derivatives As Potent Tubulin-Targeting Agents.

Design, synthesis and evaluation of novel bis-substituted aromatic amide dithiocarbamate derivatives as colchicine site tubulin polymerization inhibitors with potent anticancer activities

Synthesis and biological evaluation of novel indole derivatives containing sulfonamide scaffold as potential tubulin inhibitor

Design, Synthesis, Biological Evaluation and Molecular Modeling Study of Novel Macrocyclic Bisbibenzyl Analogues As Antitubulin Agents

Synthesis and biological evaluation of benzofuran-based 3,4,5-trimethoxybenzamide derivatives as novel tubulin polymerization inhibitors

Design and Synthesis of (2-(Phenylamino)thieno[3,2-d]pyrimidin-4-yl)(3,4,5-trimethoxyphenyl)meth Anone Analogues As Potent Anti-Tubulin Polymerization Agents

Synthesis, Biological Evaluation and Molecular Docking of Benzimidazole Grafted Benzsulfamide-Containing Pyrazole Ring Derivatives As Novel Tubulin Polymerization Inhibitors.

3-Vinylazetidin-2-Ones: Synthesis, Antiproliferative and Tubulin Destabilizing Activity in MCF-7 and MDA-MB-231 Breast Cancer Cells